Delving into the Latest Updates on KQB-168 with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

KQB-168

Target-

Action-

Mechanism-

Therapeutic Areas

Neoplasms

Active Indication

Advanced Malignant Solid Neoplasm

Inactive Indication-

Originator Organization

Kumquat Biosciences, Inc.

Active Organization

Kumquat Biosciences, Inc.

Inactive Organization-

License Organization-

Drug Highest PhasePhase 1

First Approval Date-

Regulation-

Login to view timeline

The goal of this clinical trial is to learn if KQB168 works to treat advanced solid tumor cancer in adults. It will also learn about the safety of KQB168. The main questions it aims to answer are:
* What is the safe dose of KQB168 by itself or in combination with pembrolizumab?
* Does KQB168 alone or in combination with pembrolizumab decrease the size of the tumor?
* What happens to KQB168 in the body?
Participants will:
* Take KQB168 daily, alone or in combination with pembrolizumab
* Visit the clinic about 8 times in the first 8 weeks, and then once every 3 weeks after that

Start Date24 Jun 2025

Sponsor / Collaborator

Kumquat Biosciences, Inc.

100 Clinical Results associated with KQB-168

Login to view more data

100 Translational Medicine associated with KQB-168

Login to view more data

100 Patents (Medical) associated with KQB-168

Login to view more data

100 Deals associated with KQB-168

Login to view more data